Clinical Trials
182 trialsZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC
Dana-Farber Cancer Institute
Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma
NRG Oncology
Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)
McGill University Health Centre/Research Institute of the McGill University Health Centre
Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer
University of Chicago
Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer
University of Michigan Rogel Cancer Center
TRIPLEX
Norwegian University of Science and Technology
Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases
University of Pittsburgh
BRIDGE
Mario Negri Institute for Pharmacological Research
Pembro+Chemo in Brain Mets
University of Kentucky
The UPPROACH (Upfront Intensity Modulated Proton Beam Therapy) Approach
University of Maryland, Baltimore
Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency
University of Washington
Pembrolizumab After Radiation Therapy and Chemotherapy in Limited Stage Small Cell Lung Cancer
Vanderbilt-Ingram Cancer Center
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma
University of Miami
Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients
Fundación GECP
Abequolixron (RGX-104) and Durvalumab in Lung Cancer
UNC Lineberger Comprehensive Cancer Center
Therapy De-escalation in Seminoma Stage IIA/B
Swiss Cancer Institute
Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer
Ohio State University Comprehensive Cancer Center
A Study of Sargramostim Plus Pembrolizumab with or Without Pemetrexed in Patients with Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy
Tufts Medical Center
Liver Directed RT + Chemo-immunotherapy for ES-SCLC
Columbia University
HRCC1
Azienda Policlinico Umberto I
Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer
Hoosier Cancer Research Network
A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer
Weill Medical College of Cornell University
Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer
University of Miami
To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer
Shanghai Chest Hospital
Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases
Hoosier Cancer Research Network
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies
Georgetown University
Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC).
University of Miami
Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer
Hoosier Cancer Research Network
Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Endometrial Cancer
Albert Einstein College of Medicine
Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Hoosier Cancer Research Network
Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer
Stanford University
Neoadjuvant PD-1 Antibody Plus Chemotherapy in Resectable Stage IIIA-N2 Non-Small-Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer
Albert Einstein College of Medicine
A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC
University of Nebraska
Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer
Icahn School of Medicine at Mount Sinai
Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer
Albert Einstein College of Medicine
Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Genetic Predictors of Benefit to Pembrolizumab
Columbia University
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
City of Hope Medical Center
Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer
M.D. Anderson Cancer Center
Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen
OHSU Knight Cancer Institute
Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma
University of Washington
Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC
Hoosier Cancer Research Network
Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung Cancer
Wuhan University
Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer
Big Ten Cancer Research Consortium
Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity
Washington University School of Medicine
Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells
Washington University School of Medicine
Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors
Rutgers, The State University of New Jersey